Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Allscripts, iScribe And ePhysician Racing To Put Script Devices In MD Hands

  • News

Executive Summary

Allscripts is seeking early market experience in Silicon Valley with its TouchScript hand-held prescribing device.

You may also be interested in...



Allscripts' TouchScript In 400 Practices: $1.3 Mil. From System Sales In 1999

Allscripts' TouchScript hand-held prescribing devices are in use in over 400 physician practice sites six months after its deployment, according to a Feb. 18 prospectus for a 2 mil.-share secondary offering.

Allscripts' TouchScript In 400 Practices: $1.3 Mil. From System Sales In 1999

Allscripts' TouchScript hand-held prescribing devices are in use in over 400 physician practice sites six months after its deployment, according to a Feb. 18 prospectus for a 2 mil.-share secondary offering.

Merck-Medco, Cardinal Support ParkStone Hand-Held Rx Devices

Merck-Medco and Cardinal Health Partners are backing the launch of ParkStone Medical Information Systems' hand-held prescription devices.

Table

View full table

Tags:
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS035114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By